Overarching analyses of COVID-19 vaccination strategies in healthy and immunocompromised individuals: 'Lessons learned' from the ongoing pandemic
- Funded by Netherlands Organisation for Health Research and Development (ZonMW)
- Total publications:0 publications
Grant number: 1.04301E+13
Grant search
Key facts
Disease
COVID-19Start & end year
20222025Funder
Netherlands Organisation for Health Research and Development (ZonMW)Principal Investigator
dr C. Geurts van KesselResearch Location
NetherlandsLead Research Institution
Erasmus Medisch CentrumResearch Priority Alignment
N/A
Research Category
Pathogen: natural history, transmission and diagnostics
Research Subcategory
Immunity
Special Interest Tags
N/A
Study Type
Clinical
Clinical Trial Details
Not applicable
Broad Policy Alignment
Pending
Age Group
Unspecified
Vulnerable Population
Other
Occupations of Interest
Unspecified
Abstract
More than 80% of the Dutch population has been fully vaccinated against COVID-19. Vaccinating individuals protects them from serious illness. Because the coronavirus adapts over time, protection became less. A booster vaccination was therefore offered for the first time at the beginning of 2022. The immune response induced by vaccination has been monitored in the healthy Dutch population by the Erasmus MC and the RIVM. In addition, 8 different research groups, led by medical specialists, have studied the immune response in patients with reduced immune systems. It is now possible to answer an important question: "Which vaccination strategy provides the best defense in healthy and immunocompromised individuals." By answering this question, advice for future booster vaccinations can be given per risk group. In addition, these lessons can be used to draw up vaccination recommendations in the event of future outbreaks.